{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:35:43Z","timestamp":1793144143225,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To explore the functional and anatomic outcomes of eyes with resistant diabetic macular edema undergoing a loading phase of four intravitreal faricimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Prospective research on 46 eyes with diabetic macular edema previously treated with aflibercept or ranibizumab. At baseline (V0) and each monthly follow-up examination (V1\u2013V4), we evaluated best-corrected visual acuity, optical coherence tomography, and angiography. Biomarkers such as central macular thickness, integrity of the ellipsoid zone\/external limiting membrane, hyperreflective foci, disorganization of inner retina layers, and presence\/absence of epiretinal membrane and subretinal fluid were collected, along with the vessel density (VD) in the superficial capillary plexi and deep capillary plexi and the foveal avascular zone area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Best-corrected visual acuity significantly improved from baseline to V4 (0.55 \u00b1 0.42 vs. 0.36 \u00b1 0.30 logMAR;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03). Sixty-five percent of eyes showed visual improvement during follow-up, whereas 91% showed anatomic improvement, with a mean central macular thickness reduction of 108.4\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0002). At V0, 20 eyes (43%) had irregularities of the external limiting membrane\/ellipsoid zone complex compared with 14 eyes (30%) at V4 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.28). Hyperreflective focis were visible in 87% of cases at baseline but reduced their prevalence up to 24 eyes (52%) at V4 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0005). Disorganization of inner retina layers was reported in eight eyes (17%) at baseline and resolved in three eyes. Foveal avascular zone area was stable during follow-up, as well as superficial capillary plexi's VD, whereas the parafoveal deep capillary plexi's VD significantly increased from V0 to V4 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Faricimab loading phase showed promising results in visual outcomes and structural improvement in resistant diabetic macular edema.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004449","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T12:04:20Z","timestamp":1750334660000},"page":"1313-1322","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["EFFECTS OF FARICIMAB LOADING PHASE ON DIABETIC MACULAR EDEMA IN REAL-WORLD SETTING"],"prefix":"10.1097","volume":"45","author":[{"given":"Alessandra","family":"Scampoli","sequence":"first","affiliation":[{"name":"Vitreoretinal Surgery Unit, Isola Tiberina Hospital - Gemelli Isola, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1638","authenticated-orcid":false,"given":"Matteo Mario","family":"Carl\u00e0","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, \u201cFondazione Policlinico Universitario A. Gemelli, IRCCS\u201d, Rome, Italy; and"},{"name":"Ophthalmology Department, Catholic University \u201cSacro Cuore\u201d, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Grieco","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, \u201cFondazione Policlinico Universitario A. Gemelli, IRCCS\u201d, Rome, Italy; and"},{"name":"Ophthalmology Department, Catholic University \u201cSacro Cuore\u201d, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Catalani","sequence":"additional","affiliation":[{"name":"Vitreoretinal Surgery Unit, Isola Tiberina Hospital - Gemelli Isola, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Governatori","sequence":"additional","affiliation":[{"name":"Vitreoretinal Surgery Unit, Isola Tiberina Hospital - Gemelli Isola, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislao","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, \u201cFondazione Policlinico Universitario A. Gemelli, IRCCS\u201d, Rome, Italy; and"},{"name":"Ophthalmology Department, Catholic University \u201cSacro Cuore\u201d, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomaso","family":"Caporossi","sequence":"additional","affiliation":[{"name":"Vitreoretinal Surgery Unit, Isola Tiberina Hospital - Gemelli Isola, Rome, Italy;"},{"name":"Ophthalmology Department, Catholic University \u201cSacro Cuore\u201d, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260323","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"R2-20260323","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"R3-20260323","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"R4-20260323","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Diabetic Retinopathy Clinical Research","year":"2010","journal-title":"Ophthalmology"},{"key":"R5-20260323","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R6-20260323","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"R7-20260323","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1136\/bjophthalmol-2019-315199","article-title":"Real-world management of treatment-na\u00efve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study","volume":"104","author":"Shimura","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R8-20260323","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"R9-20260323","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"R10-20260323","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/medicina59040665","article-title":"Short-term outcomes of intravitreal faricimab injection for diabetic macular edema","volume":"59","author":"Kusuhara","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"R11-20260323","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/medicina59061125","article-title":"Faricimab for diabetic macular edema in patients refractory to ranibizumab or aflibercept","volume":"59","author":"Ohara","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"R12-20260323","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","article-title":"Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME","volume":"10","author":"Penha","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"R13-20260323","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2147\/OPTH.S424315","article-title":"One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration","volume":"17","author":"Rush","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"R14-20260323","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.3390\/jcm13154508","article-title":"Short-term clinical outcomes of patients with diabetic macular edema following a therapy switch to faricimab","volume":"13","author":"Wolfrum","year":"2024","journal-title":"J Clin Med"},{"key":"R15-20260323","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00417-017-3624-y","article-title":"Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema","volume":"255","author":"Bahrami","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R16-20260323","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajo.2015.12.030","article-title":"Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema","volume":"164","author":"Rahimy","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R17-20260323","first-page":"423","article-title":"Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab","volume":"10","author":"Lim","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"R18-20260323","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/bjo-2023-324394","article-title":"Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema","volume":"108","author":"Durrani","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"R19-20260323","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10792-024-03226-2","article-title":"Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema","volume":"44","author":"Pichi","year":"2024","journal-title":"Int Ophthalmol"},{"key":"R20-20260323","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s40123-024-00980-5","article-title":"Real-world outcomes of a loading phase with intravitreal faricimab in neovascular age-related macular degeneration (n-AMD) and diabetic macular edema (DME)","volume":"13","author":"Giancipoli","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"R21-20260323","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema","volume":"132","author":"Sun","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R22-20260323","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/IAE.0000000000001687","article-title":"Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema: the CHARTRES Study","volume":"38","author":"Santos","year":"2018","journal-title":"Retina"},{"key":"R23-20260323","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1167\/iovs.09-4493","article-title":"Optical coherence tomography may be used to predict visual acuity in patients with macular edema","volume":"52","author":"Pelosini","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R24-20260323","doi-asserted-by":"crossref","first-page":"e2675","DOI":"10.1371\/journal.pone.0002675","article-title":"The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy","volume":"3","author":"Kuiper","year":"2008","journal-title":"PLoS One"},{"key":"R25-20260323","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s10792-013-9884-6","article-title":"Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities","volume":"34","author":"Yoon","year":"2014","journal-title":"Int Ophthalmol"},{"key":"R26-20260323","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1007\/s00417-024-06518-6","article-title":"The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema","volume":"262","author":"Maguire","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R27-20260323","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1080\/09273948.2019.1704028","article-title":"OCT angiography study of the macula in patients with diabetic macular edema treated with intravitreal aflibercept","volume":"29","author":"Dastiridou","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"R28-20260323","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1167\/iovs.16-20579","article-title":"Optical coherence tomography angiography analysis of the foveal avascular zone and macular vessel density after anti-VEGF therapy in eyes with diabetic macular edema and retinal vein occlusion","volume":"58","author":"Ghasemi Falavarjani","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-20260323","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"R30-20260323","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41598-018-38248-1","article-title":"Retinal microvasculature and visual acuity after intravitreal aflibercept in diabetic macular edema: an optical coherence tomography angiography study","volume":"9","author":"Busch","year":"2019","journal-title":"Sci Rep"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:00:38Z","timestamp":1774270838000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004449"}},"subtitle":["An Optical Coherence Tomography Angiography Study"],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004449","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}